J. Matthew Singleton, Director at Viking Therapeutics, Inc. (VKTX), sold 41,412 shares at $57.52 ($2.4M) on 2024-08-14, disclosed to the SEC on 2024-08-14.
Scheduled sale ($2.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $57.52 | 20,626 | $1.2M | 49.8% |
| 2 | $57.52 | 20,626 | $1.2M | 49.8% |
| 3 | $58.37 | 160 | $9K | 0.4% |
| Total | $57.52 avg | 41,412 | $2.4M | 100% |
| Filing → |
| VKTX | SELL | 2024-08-22 | $397K | — | Filing → |
| VKTX | SELL | 2024-08-19 | $1.8M | — | Filing → |
| VKTX | BUY | 2018-05-31 | $93K | — | Filing → |